Literature DB >> 29661022

Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV.

Kristine M Erlandson1, Amber Streifel2, Alexander R Novin2, Kellie L Hawkins1,3, Clayton Foster1, Jacob Langness2, Mary Bessesen1,4, Julian Falutz5, Abeer Moanna6,7, David Looney8,9, Scott T Johns10, Joseph B Nguyen10, Michael N Oxman8,9, Myron J Levin11.   

Abstract

Herpes zoster (HZ) occurs at a higher age-specific rate in people living with HIV (PLWH) than in the general population. We implemented a quality improvement study to assess herpes zoster vaccine (HZV) usage among PLWH, assess HZV usage after additional reminders/prompts, and identify barriers to HZV among older PLWH. HZV rates in PLWH were determined in six institutions with varying payment structures. For the intervention, Part 1, PLWH eligible for HZV at the University of Colorado were identified, and providers were notified of patient eligibility. In Part 2, in addition to provider notification, an order for HZV was placed in the patient's chart before a clinic appointment. HZ vaccination rates ranged from 1.5% to 42.4% at six sites. Before the intervention, 21.3% of eligible University of Colorado patients had received HZV. An additional 8.3% received HZV with Part 1 and 17.8% with Part 2 interventions. At completion, a total of 53.2% of eligible patients had received HZV through routine clinical care or the interventions. Insurance coverage concern was cited as a common reason for not receiving HZV. Minor adverse reactions occurred in 26.7% patients and did not require medical care. HZV coverage was low at a majority of sites. Clinical reminders with links to vaccination orders or preplaced vaccination orders led to improved HZV coverage in our clinic, but published guidelines for use of HZV in PLWH and improvement in logistic or insurance barriers to HZV receipt are paramount to improved HZV coverage.

Entities:  

Keywords:  HIV; frail elderly; herpes zoster; herpes zoster vaccine; immunization schedule

Mesh:

Substances:

Year:  2018        PMID: 29661022      PMCID: PMC6025846          DOI: 10.1089/AID.2017.0315

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Evaluation of Herpes Zoster Vaccination in HIV-Infected Patients 50 Years of Age and Older.

Authors:  Chelsea Bombatch; Andrea Pallotta; Elizabeth A Neuner; Alan J Taege
Journal:  Ann Pharmacother       Date:  2016-02-09       Impact factor: 3.154

Review 2.  Systematic review of interventions to increase influenza vaccination rates of those 60 years and older.

Authors:  Roger E Thomas; Margaret L Russell; Diane L Lorenzetti
Journal:  Vaccine       Date:  2009-12-14       Impact factor: 3.641

3.  Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.

Authors:  Constance A Benson; Janet W Andersen; Bernard J C Macatangay; Robbie B Mailliard; Charles R Rinaldo; Sarah Read; Dawn R Bozzolo; Lynette Purdue; Cheryl Jennings; Michael C Keefer; Marshall Glesby; Pablo Tebas; Amy Falk Russell; Jason Martin; Paula Annunziato; Zoran Popmihajlov; Jeffrey L Lennox
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

4.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Authors:  Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

5.  Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

Authors:  Myron J Levin; Kenneth E Schmader; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

6.  Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.

Authors:  Sophie Grabar; Pierre Tattevin; Hana Selinger-Leneman; Arnaud de La Blanchardiere; Pierre de Truchis; Christian Rabaud; David Rey; Vincent Daneluzzi; Samuel Ferret; Anne-Sophie Lascaux; Thomas Hanslik; Dominique Costagliola; Odile Launay
Journal:  Clin Infect Dis       Date:  2015-01-18       Impact factor: 9.079

7.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 8.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 9.  What does epidemiology tell us about risk factors for herpes zoster?

Authors:  Sara L Thomas; Andrew J Hall
Journal:  Lancet Infect Dis       Date:  2004-01       Impact factor: 25.071

10.  Providers' lack of knowledge about herpes zoster in HIV-infected patients is among barriers to herpes zoster vaccination.

Authors:  M Aziz; H Kessler; G Huhn
Journal:  Int J STD AIDS       Date:  2013-07-19       Impact factor: 1.359

View more
  3 in total

1.  Herpes Zoster Rates Continue to Decline in People Living With Human Immunodeficiency Virus but Remain Higher Than Rates Reported in the General US Population.

Authors:  Laura Gilbert; Xun Wang; Robert Deiss; Jason Okulicz; Ryan Maves; Christina Schofield; Tomas Ferguson; Timothy Whitman; Karl Kronmann; Brian Agan; Anuradha Ganesan
Journal:  Clin Infect Dis       Date:  2019-06-18       Impact factor: 9.079

Review 2.  HIV and Aging: Reconsidering the Approach to Management of Comorbidities.

Authors:  Kristine M Erlandson; Maile Y Karris
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

3.  Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study.

Authors:  Kellie L Hawkins; Kirsha S Gordon; Myron J Levin; Adriana Weinberg; Catherine Battaglia; Maria C Rodriguez-Barradas; Sheldon T Brown; David Rimland; Amy Justice; Janet Tate; Kristine M Erlandson
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.